Bravecto Quantum Receives FDA Approval
Bravecto Quantum, a single-use injectable parasiticide offering 12 months of protection for dogs, has been approved by the US Food and Drug Administration (FDA). This injectable treatment is now accessible to veterinary professionals across the United States.
Global Approvals and Availability
Since its initial approval in 2023 for Australia and New Zealand, Bravecto Quantum has gained authorization in more than 50 countries, including the European Union last year. Merck Animal Health, the product’s manufacturer, expects it to be stocked in veterinary practices and hospitals nationwide within the upcoming month.
Product Benefits and Coverage
- Suitable for dogs and puppies aged six months and older
- Delivers full-year protection with just one dose
- Protects against fleas (Ctenocephalides felis)
- Guards against black-legged ticks (Ioxedes scapularis), American dog ticks (Dermacentor variabilis), and brown dog ticks (Rhipicephalus sanguineus) for 12 months
- Provides eight months of coverage for lone star ticks (Amblyomma americanum)
"This approval sets a new standard in pet care by providing veterinarians and pet parents with a safe and effective option when it comes to flea and tick protection for dogs." — Christine Royal, Merck Animal Health Vice-President and Veterinarian
Summary: Bravecto Quantum offers veterinarians and pet owners a unique annual injectable solution, combining convenience and long-lasting protection against multiple ticks and fleas for dogs.